CML Does Not Affect Antibody Development Against SARS-CoV-2 - Cancer Therapy Advisor

Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.

Patients with chronic myeloid leukemia (CML) predominantly on active treatment are still able to mount an antibody response against SARS-CoV-2, according to research published in conjunction with the… [+2993 chars]

full article...